<DOC>
	<DOCNO>NCT01766726</DOCNO>
	<brief_summary>The main aim study determine whether : ) ART-naïve HIV+ subject increase artherosclerotic plaque inflammation/vulnerability , b ) newly-initiated QUAD/Stribild therapy decrease plaque inflammation/vulnerability subject , c ) QUAD/Stribild therapy improve index immune dysregulation lipid dysfunction mechanism improve plaque inflammation/vulnerability . Parameters lipid immune function also assess healthy control subject , comparison .</brief_summary>
	<brief_title>Effects Newly-Initiated QUAD Therapy Aortic/Coronary Inflammation ART-Naïve Infected Patients</brief_title>
	<detailed_description>Patients HIV high risk morbidity mortality cardiovascular disease healthy subject . Antiretroviral therapy ( ART ) greatly increase lifespan HIV+ patient , risk CVD remain high normal . Previously , show compare healthy control subject , ART-treated HIV+ patient atherosclerotic plaque inflammation aorta . This study intend determine whether atherosclerotic plaque inflammation/vulnerability increase ART-naïve HIV+ patient whether parameter improve 6 month newly-initiated QUAD/Stribild therapy . Additionally , study determine whether index immune dysregulation lipid dysfunction increase ART-naive HIV+ patient whether parameter also improve 6 month newly initiate QUAD/Stribild therapy .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<criteria>HIVinfected Subjects : men woman , age 18+ , document HIVinfection ARTnaive ready start ART QUAD/Stribild treat infectious disease doctor history prior , sustain ART use CD4 &lt; 50 AIDSdefining illness know current opportunistic infection acute infection ( include Hepatitis B/C ) pregnancy breastfeed history acute coronary syndrome coronary artery stenting surgery , diabetes mellitus , significant autoimmune/inflammatory disease plan sustain use 6 month study interval confound immune suppressant medication include intravenous oral corticosteroid hemoglobin &lt; 12.5 g/dl men &lt; 12 g/dl woman eGFR &lt; 70 ml/min/1.73 m2 calculate CDKEPI contrast dye allergy contraindication beta blocker nitroglycerin administer MDCT coronary angiography ( coronary CTA ) protocol body weight &gt; 320 lb ( PET scanner limitation ) significant radiation exposure ( &gt; 2 myocardial perfusion scan CT angiogram ) receive within past year report active illicit drug use Healthy control subject : men woman , age 18+ , without HIV infection know current opportunistic infection acute infection ( include Hepatitis B/C ) pregnancy breastfeed history acute coronary syndrome coronary artery stenting surgery , diabetes mellitus , significant autoimmune/inflammatory disease sustain use confound immune suppressant medication include intravenous oral corticosteroid hemoglobin &lt; 12.5 g/dl men &lt; 12 g/dl woman report active illicit drug use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>